Deeper Than "Ozempic Face": What GLP-1 Medications May Really Be Doing to Your Facial Structure

The conversation around GLP-1 medications and appearance has largely centered on "Ozempic face," the gaunt, hollowed look that can accompany rapid weight loss. But according to Konstantin Vasyukevich, M.D., a leading facelift expert based in New York City, the visible changes patients notice in the mirror may reflect something deeper than fat loss alone.

As GLP-1 medications become increasingly mainstream, more patients are arriving at aesthetic consultations with concerns that go beyond wrinkles or sagging skin. They are noticing temple hollowing, midface flattening and a general deflation that makes them look older or unlike themselves, often faster than they anticipated. Vasyukevich is helping patients understand what is actually happening beneath the surface, what steps can be taken early to protect both bone health and facial structure, and when it makes sense to explore aesthetic options. His message is less about alarm and more about informed, proactive care.

Beyond the facial volume loss people associate with “Ozempic face,” how exactly does rapid weight loss from GLP-1 medications potentially affect the underlying bone structure of the face?
Konstantin Vasyukevich, M.D.: We do not yet have strong evidence that GLP-1 medications directly cause facial bone loss, but rapid weight loss can reduce the fat, muscle and soft-tissue support that gives the face its structure. As that support decreases, normal age-related skeletal changes may become more noticeable.

What are the earliest signs that someone’s facial changes on a GLP-1 medication may be related to bone density rather than just fat loss?
KV: It is difficult to determine bone-density changes by appearance alone, and most early facial changes are more likely related to fat loss and soft-tissue laxity. Signs such as temple hollowing, under-eye hollowing, midface flattening, or increased jawline laxity may suggest loss of deeper support, but true bone health concerns should be evaluated medically.

For patients planning to be on these medications long term, how concerned should they be about bone health, and is this something they should be discussing with their prescribing physician?
KV: Patients should discuss bone health with the physician managing their GLP-1 medication, especially if they are losing weight quickly or have risk factors such as menopause, low bone density, nutritional deficiencies or prior fractures. The goal is not to create fear but to ensure weight loss is medically supervised in a way that protects muscle, nutrition and bone health.

What proactive steps, such as protein intake or resistance training, can patients take early on to help protect both their bone health and their facial structure while losing weight?
KV: Focus on preserving lean muscle and structural support through adequate protein intake, resistance training, hydration and vitamin support. From a facial rejuvenation perspective, slower, well-supported weight loss may help reduce the hollow or deflated look some patients notice with rapid weight loss.

At what point should someone consider an aesthetic consultation, and what options exist for patients who are already noticing these changes?
KV: Patients should consider an aesthetic consultation when their facial changes make them feel older, hollow, tired or unlike themselves, ideally once their weight is stable or close to stable. Surgical options can include face and neck lifts, blepharoplasty or fat grafting.